Abbvie (ABBV) Stock
Established biopharmaceutical company with strong cash flow. Here's the price, business snapshot, and what's worth knowing about Abbvie in July 2026.
AbbVie Inc (ABBV) is a large-cap biopharmaceutical company known for established prescription medicines and an expanding pipeline. Historically driven by a few high-revenue products, AbbVie has sought to diversify through R&D, new product launches and acquisitions. The company generates significant free cash flow and is a regular dividend payer, which may attract income-focused investors. Key considerations for potential investors include patent and competition risks (including biosimilars), the outcome of clinical trials, regulatory approvals and pricing pressure in major markets. Market-cap scale and a broad geographic footprint can offer resilience, but revenues can be volatile around patent cliffs and product lifecycle events. This summary is for general educational purposes only and is not personal investment advice; investors should assess their own risk tolerance, time horizon and seek independent advice before acting. Past performance is not a guide to future results.
Why It’s Moving
AbbVie edges on steady analyst support as investors weigh how much growth is already in the price.
- AbbVie is moving mostly on analyst sentiment rather than fresh company news, with Wall Street still broadly positive but less euphoric than before.
- The market is focusing on the durability of Skyrizi and Rinvoq, which remain the key growth engines supporting the stock’s longer-term story.
- Some analysts now argue that a lot of AbbVie’s growth is already priced in, which is tempering upside expectations even as the consensus remains constructive.
AbbVie edges on steady analyst support as investors weigh how much growth is already in the price.
- AbbVie is moving mostly on analyst sentiment rather than fresh company news, with Wall Street still broadly positive but less euphoric than before.
- The market is focusing on the durability of Skyrizi and Rinvoq, which remain the key growth engines supporting the stock’s longer-term story.
- Some analysts now argue that a lot of AbbVie’s growth is already priced in, which is tempering upside expectations even as the consensus remains constructive.
When is the next earnings date for AbbVie (ABBV)?
AbbVie’s next earnings date is expected on July 30–31, 2026, with multiple market sources pointing to July 31, 2026 before the market opens. The report will cover Q2 2026 results. This date is consistent with AbbVie’s typical late-July earnings pattern.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying AbbVie’s stock as it has potential to reach a higher price.
Financial Health
AbbVie is achieving strong profits and revenue, supported by healthy cash flow and margins.
Dividend
AbbVie's dividend yield of 2.61% indicates a moderate payout to shareholders. If you invested $1000 you would be paid $26.10 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ASTRAZENECA PLC
AstraZeneca is a global biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing innovative medicines.
AMGEN INC
Amgen is a global biotechnology company that focuses on discovering, developing and commercializing treatments for unmet medical needs.
BRIDGEBIO PHARMA INC
BridgeBio Pharma, Inc. is a biopharmaceutical company. It discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases. Its pipeline of development programs ranges from early science to advanced clinical trials, which includes Attruby, an oral small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); Beyonttra for the treatment of TTR Amyloidosis; Low-dose Infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI) for the treatment of children with achondroplasia and hypochondroplasia; Encaleret, an oral small molecule antagonist of the calcium sensing receptor (CaSR) that it is developing for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, for the treatment of Limb Girdle Muscular Dystrophy Type 2I. It also conducting a Phase 1/2 study (CANaspire) for BBP-812 for Canavan disease.
Baskets Featuring ABBV
TYK2 Inhibitors: Might Oral Drugs Rule Autoimmune?
Alumis's breakthrough trial results for its oral psoriasis drug have highlighted the massive potential of advanced autoimmune therapies. This theme focuses on the pharmaceutical companies pioneering next-generation oral treatments, particularly selective TYK2 inhibitors, which represent a new frontier in convenient and effective patient care.
Published: 7 January 2026
Explore BasketDrug Pricing Power | Major Pharma Stocks 2025
Following plans by major drugmakers to raise prices on hundreds of medications, the pharmaceutical industry is showcasing its significant pricing power. This development highlights an investment opportunity centered on established pharmaceutical companies capable of translating market dominance into revenue growth.
Published: 2 January 2026
Explore BasketCancer Therapies: What's Next After 100% Response Rate
Regeneron's announcement of a 100% response rate for its new lymphoma therapy highlights a major advancement in cancer treatment. This breakthrough creates an investment opportunity centered on companies pioneering next-generation immuno-oncology drugs, particularly those developing bispecific antibodies and other innovative platforms.
Published: 7 December 2025
Explore BasketRinvoq vs Humira Results | Immunology Market Shift
AbbVie's new arthritis drug, Rinvoq, has proven superior to its predecessor, Humira, signaling a major shift in the immunology market. This theme focuses on the innovative pharmaceutical companies poised to benefit from the demand for more effective autoimmune disease treatments.
Published: 21 October 2025
Explore BasketBeyond The Patent Cliff: Pharma's New Growth Engines
AbbVie raised its profit outlook, proving it can thrive after its blockbuster Humira faced competition. This creates an investment opportunity in resilient pharmaceutical companies that are successfully launching new drugs to replace older ones.
Published: 1 August 2025
Explore BasketPharma's Renewed Focus On Mental Health
AbbVie's potential $1 billion acquisition of Gilgamesh Pharmaceuticals signals a major strategic investment in the mental health sector. This move is expected to increase M&A interest and valuations for other biotech firms developing innovative psychiatric therapies.
Published: 31 July 2025
Explore BasketNext-Gen Multiple Myeloma Treatments
Discover biotech companies at the forefront of revolutionary cancer treatments. These carefully selected stocks represent innovators developing cutting-edge immunotherapies for multiple myeloma, a common blood cancer with significant unmet medical needs.
Published: 3 July 2025
Explore BasketMarket Indecision
Find refuge from market volatility with these carefully selected companies providing essential goods and services. Our professional analysts have handpicked high-quality, dividend-paying stocks in defensive sectors that offer stability when economic futures look uncertain.
Published: 18 June 2025
Explore BasketEmpire Builders
These companies are led by visionaries who excel at growing through smart acquisitions. Our analysts have carefully selected businesses with proven ability to buy competitors, integrate them successfully, and build lasting market power.
Published: 17 June 2025
Explore BasketWhy You’ll Want to Watch This Stock
Large-cap pharma value
Generates strong cash flows and has a track record of dividends, which may suit income-oriented allocations — though yields and share performance can fluctuate.
Pipeline and innovation
New drug approvals and successful trials can drive growth, but R&D outcomes are uncertain and clinical setbacks are possible.
Global market exposure
A broad geographic footprint diversifies revenue sources, while differing regulations and pricing environments create both opportunity and risk.
Compare AbbVie with other stocks
AbbVie vs Bristol Myers Squibb
AbbVie vs Bristol Myers Squibb: Stock Comparison
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
